| Objective To investigate the clinical efficacy of selenium yeast intervention on patients with autoimmune thyroiditis (AIT) by comparing the levels of thyroid-stimulating hormone (TSH), free thyroxine (FT4), th-yroid peroxidase antibody (TPOAb) and selenium in serum after treatment with those at baseline. To explore the depression of TPOAb caused by selenium yeast. To find an effective treatment to early AIT.Methods 56 outpatients with AIT (TPOAb>300 IU/ml, normal FT4, normal or elevated TSH) were recruited into two groups, and each group was randomly divided into Selenium group (Se group) and placebo group (Con group) respectively. In group I, the patients with normal thyroid function, treated with selenium yeast, Patients in Group II had normal thyroid function but received placebo. In group III, the patients had subclinical hypothyroidism. Patients in Group IV had subclinical hypothyroidism but received placebo. The intervention was performed as following: taking 100μg selenium yeast or placebo , Bid, Pro, for 6 months. Moreover, drug response and patient compliance were studied at the first month, second month, fourth month, fifth month. Serum concentration of TPOAb, TSH, FT4, Se and biochemical changes were all measured at the third and sixth months of treatment. T-test and ANOVA was used to analysis the data an by SPSS 17.0, p<0.05 was set to be as significant.Results1. 56 AIT patients have been followed up for 6 months. Among 56 patients, 41 Euthyroid patients were divided into two groups randomly, a) 19 patients (all female) in Se group with averge age (45.7±11.2). b) 22 patients (18 female and 4 male) in Con group with averge age (46.3±14.2). 15 Subclinical hypothyroidism patients were also divided into two groups randomly. c) 7 patients (6 female and 1 male) in Se group with averge age (44.3±9.7). d) 8 patients (all female) in Con group with averge age (47.3±12.7).2. With 6 months Se supplementation, the basal serum concentrations of Se group were raised significantly (154.5±47.6μg/l & 113.2±21.2μg/l, P<0.05). Basal serum concentrations of Con group showed no difference (101.1±10.9μg/l & 103.3±13.6μg/l, P>0.05). The Se group rised significantly compared to Con group (P<0.05).3. In 41 Euthyroid patients, serum TSH level shows no significant differeneces between Se group (3.2±1.8 mU/L & 3.4±2.8 mU/L)and Con group (15.4±2.3 mU/L & 2.7±1.2 mU/L). ( P>0.05). Serum FT4 shows no significant differeneces between Se group (16.1±1.7 pmol/L &15.4±2.4 pmol/L )and Con group (15.4±2.3 pmol/L & 16.2±2.8 pmol/L, P>0.05). In 15 Subclinical hypothyroidism patients serum TSH shows no significant differeneces between Se group (5.6±1.2 mU/L & 5.9±2.7 mU/L)and Con group (8.4±5.6 mU/L & 8.3±4.5 mU/L, P>0.05). Serum FT4 shows no significant differeneces between Se group (14.7±1.3 pmol/L &14.9±1.2 pmol/L ) and Con group (13.3±3.9 pmol/L & 14.0±2.8 pmol/L, P>0.05).4. In 41 Euthyroid patients TPOab shows no significant differeneces between Se group(945.0 IU/ml &1175.0 IU/ml)and Con group (698.5IU/ml & 812.0IU/ml, P>0.05). In 15 Subclinical hypothyroidism patients TPOab shows no significant differeneces between Se group (1380.0IU/ml & 1140.0IU/ml) and Con group (1169.5IU/ml & 1190.0 IU/ml, P>0.05).ConclusionSelenium therapy has no effect on serum levels of TSH, FT4 and TPOAb for early AIT patients. |
PDF Full Text Request